Literature DB >> 19155972

Development of a humanized mouse model to study the role of macrophages in allograft injury.

Nancy C Kirkiles-Smith1, Martha J Harding, Benjamin R Shepherd, Stacey A Fader, Tai Yi, Yinong Wang, Jennifer M McNiff, Edward L Snyder, Marc I Lorber, George Tellides, Jordan S Pober.   

Abstract

BACKGROUND: Nearly half of all infiltrating leukocytes in rejecting human allografts are macrophages, yet, in comparison with T cells, much less is known about the contribution of this cell type to rejection. Our laboratory has previously described models of rejection of human skin or artery grafts in immunodeficient mouse hosts mediated by adoptively transferred allogeneic T cells. However, mature human monocyte/macrophages have consistently failed to engraft in these animals. Here, we describe the introduction of human CD68+ macrophages into irradiated immunodeficient mice by transplantation of enriched CD34+ hematopoietic stem-cells isolated from peripheral blood of G-colony-stimulating factor pretreated adults.
METHODS: We investigated strains of immunodeficient mice bearing human tissue grafts (skin and artery) inoculated with 1 x 10(6) human CD34+ adult hematopoietic stem cells, peripheral blood monuclear cells autologous to the CD34 donor, or both for human cell engraftment.
RESULTS: In the absence of T cells, CD68+ CD14+ macrophages infiltrate allogeneic human skin but produce little injury or thrombosis. Both responses are enhanced when combined with adoptive transfer of T cells autologous to the hematopoietic stem cells as exemplified by the induction of the macrophage activation marker CD163. CD68+ macrophages also infiltrate allogeneic arterial interposition grafts, producing intimal expansion and calcification in the absence of T cells.
CONCLUSIONS: These new models may be used to study the role of human macrophages in transplant rejection and other pathologies in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19155972      PMCID: PMC2776641          DOI: 10.1097/TP.0b013e318192e05d

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  39 in total

Review 1.  Biology of calcification in vascular cells: intima versus media.

Authors:  D Proudfoot; C M Shanahan
Journal:  Herz       Date:  2001-06       Impact factor: 1.443

2.  Development of a human adaptive immune system in cord blood cell-transplanted mice.

Authors:  Elisabetta Traggiai; Laurie Chicha; Luca Mazzucchelli; Lucio Bronz; Jean-Claude Piffaretti; Antonio Lanzavecchia; Markus G Manz
Journal:  Science       Date:  2004-04-02       Impact factor: 47.728

Review 3.  Vascular calcification in chronic kidney disease.

Authors:  William G Goodman; Gerard London; Kerstin Amann; Geoffrey A Block; Cecilia Giachelli; Keith A Hruska; Markus Ketteler; Adeera Levin; Ziad Massy; David A McCarron; Paolo Raggi; Catherine Mary Shanahan; Noriaki Yorioka
Journal:  Am J Kidney Dis       Date:  2004-03       Impact factor: 8.860

4.  Antigenic heterogeneity of human mononuclear phagocytes: immunohistologic analysis using monoclonal antibodies.

Authors:  W W Hancock; H Zola; R C Atkins
Journal:  Blood       Date:  1983-12       Impact factor: 22.113

5.  Macrophages act as effectors of tissue damage in acute renal allograft rejection.

Authors:  Matthew D Jose; Yohei Ikezumi; Nico van Rooijen; Robert C Atkins; Steven J Chadban
Journal:  Transplantation       Date:  2003-10-15       Impact factor: 4.939

6.  Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).

Authors:  Allan D Kirk; Douglas A Hale; Roslyn B Mannon; David E Kleiner; Steven C Hoffmann; Robert L Kampen; Linda K Cendales; Douglas K Tadaki; David M Harlan; S John Swanson
Journal:  Transplantation       Date:  2003-07-15       Impact factor: 4.939

7.  Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads.

Authors:  Terence M Doherty; Kamlesh Asotra; Lorraine A Fitzpatrick; Jian-Hua Qiao; Douglas J Wilkin; Robert C Detrano; Colin R Dunstan; Prediman K Shah; Tripathi B Rajavashisth
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

8.  Monocyte-mediated acute renal rejection after combined treatment with preoperative Campath-1H (alemtuzumab) and postoperative immunosuppression.

Authors:  Ping L Zhang; Sayeed K Malek; Jeffery W Prichard; Fan Lin; Taher M Yahya; Michael S Schwartzman; Ruth P Latsha; Marybess Skaletsky; Evan R Norfolk; Robert E Brown; James E Hartle; Santosh Potdar
Journal:  Ann Clin Lab Sci       Date:  2004       Impact factor: 1.256

Review 9.  Regulation of cardiovascular calcification.

Authors:  Mei Y Speer; Cecilia M Giachelli
Journal:  Cardiovasc Pathol       Date:  2004 Mar-Apr       Impact factor: 2.185

10.  Transfer of a functional human immune system to mice with severe combined immunodeficiency.

Authors:  D E Mosier; R J Gulizia; S M Baird; D B Wilson
Journal:  Nature       Date:  1988-09-15       Impact factor: 49.962

View more
  18 in total

1.  Co-Expression Analysis Reveals Mechanisms Underlying the Varied Roles of NOTCH1 in NSCLC.

Authors:  Sara L Sinicropi-Yao; Joseph M Amann; David Lopez Y Lopez; Ferdinando Cerciello; Kevin R Coombes; David P Carbone
Journal:  J Thorac Oncol       Date:  2018-11-05       Impact factor: 15.609

Review 2.  Humanized mice for immune system investigation: progress, promise and challenges.

Authors:  Leonard D Shultz; Michael A Brehm; J Victor Garcia-Martinez; Dale L Greiner
Journal:  Nat Rev Immunol       Date:  2012-10-12       Impact factor: 53.106

3.  Humanized mouse models to study human diseases.

Authors:  Michael A Brehm; Leonard D Shultz; Dale L Greiner
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2010-04       Impact factor: 3.243

Review 4.  Human allograft rejection in humanized mice: a historical perspective.

Authors:  Michael A Brehm; Leonard D Shultz
Journal:  Cell Mol Immunol       Date:  2012-02-13       Impact factor: 11.530

5.  NOD-scid IL2rgamma(null) mouse model of human skin transplantation and allograft rejection.

Authors:  Waldemar J Racki; Laurence Covassin; Michael Brehm; Stephen Pino; Ronald Ignotz; Raymond Dunn; Joseph Laning; Susannah K Graves; Aldo A Rossini; Leonard D Shultz; Dale L Greiner
Journal:  Transplantation       Date:  2010-03-15       Impact factor: 4.939

6.  An implantable vascularized protein gel construct that supports human fetal hepatoblast survival and infection by hepatitis C virus in mice.

Authors:  Martha J Harding; Christin M Lepus; Thomas F Gibson; Benjamin R Shepherd; Scott A Gerber; Morven Graham; Frank X Paturzo; Christoph Rahner; Joseph A Madri; Alfred L M Bothwell; Brett D Lindenbach; Jordan S Pober
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

7.  Human proangiogenic circulating hematopoietic stem and progenitor cells promote tumor growth in an orthotopic melanoma xenograft model.

Authors:  Julie A Mund; Harlan Shannon; Anthony L Sinn; Shanbao Cai; Haiyan Wang; Kamnesh R Pradhan; Karen E Pollok; Jamie Case
Journal:  Angiogenesis       Date:  2013-07-23       Impact factor: 9.596

Review 8.  Humanized Mouse Models of Clinical Disease.

Authors:  Nicole C Walsh; Laurie L Kenney; Sonal Jangalwe; Ken-Edwin Aryee; Dale L Greiner; Michael A Brehm; Leonard D Shultz
Journal:  Annu Rev Pathol       Date:  2016-12-05       Impact factor: 23.472

Review 9.  Humanized Mouse Models for Transplant Immunology.

Authors:  L L Kenney; L D Shultz; D L Greiner; M A Brehm
Journal:  Am J Transplant       Date:  2015-11-20       Impact factor: 8.086

10.  Comparison of human fetal liver, umbilical cord blood, and adult blood hematopoietic stem cell engraftment in NOD-scid/gammac-/-, Balb/c-Rag1-/-gammac-/-, and C.B-17-scid/bg immunodeficient mice.

Authors:  Christin M Lepus; Thomas F Gibson; Scott A Gerber; Ivana Kawikova; Marian Szczepanik; Jaber Hossain; Vitaly Ablamunits; Nancy Kirkiles-Smith; Kevan C Herold; Ruben O Donis; Alfred L Bothwell; Jordan S Pober; Martha J Harding
Journal:  Hum Immunol       Date:  2009-06-12       Impact factor: 2.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.